FDA Cites Gleevec For Promoting Unapproved Indications Three Weeks Before Expanding Label
This article was originally published in The Pink Sheet Daily
Executive Summary
Notice of violation letter to Novartis from FDA’s Office of Prescription Drug Promotion expresses concern about describing a patient with five-year survival data, a claim that was added to the label the following month.
You may also be interested in...
Kisqali ‘Live Longer’ TV Ad Misrepresents Patient-Reported Outcome Data, US FDA Tells Novartis
Untitled letter says advertisement could lead breast cancer patients to believe Kisqali has better overall survival and quality of life than was demonstrated. FDA also criticizes length of time to read claims in superimposed text and competing audio and visual presentations in the TV spot.
Copaxone Promos Can’t List Risks Product Doesn’t Have, Especially Incorrectly, FDA Warns
The first warning letter of the year from FDA’s Office of Prescription Drug Promotion goes to Teva for web pages and materials displayed at a medical conference that overstated the safety and efficacy of its MS drug Copaxone.
Gleevec Extends Post-Surgery GIST Survival Significantly; Wins Full Adjuvant Approval
Patients who took Novartis’ Gleevec for three years after surgery to remove gastrointestinal stromal tumors had a 54% reduction in risk of recurrence and a 55% reduction in risk of death compared to patients who took it for only one year.